Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma MOST POPULAR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... August 25, 2023 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer June 30, 2025 Load more HOT NEWS Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers
